Reclaiming the immune system's assault on tumors
One of the major obstacles with treating cancer is that tumors can conscript the body's immune cells and make them work for them. Researchers at EPFL have now found a way to reclaim the corrupted immune cells, turn them into signals for the immune system to attack the tumor, and even prevent metastasis.

A microscope photograph showing immune cells (green) attacking tumor cells (red).
Michele De Palma/EPFL
Macrophages are cells of the immune system that protect the host from invading pathogens. But in cancer, macrophages can be "hijacked" by tumors, and made to support their malignant growth and spread. This is a drawback for a major cancer treatment, immunotherapy, which turns the body's immune system against the tumor. EPFL scientists, working with colleagues at the Roche Innovation Centers in Munich and Basel, have now identified a molecular "switch" that can convert the "hijacked" macrophages into cells that can stimulate the immune system to fight the growth and spread of cancer.
"Traitor" macrophages
Along with attacking foreign pathogens like bacteria, macrophages also help the body's organs develop and its wounds heal. Their own behavior is fine-tuned by small molecules that they produce, called microRNAs.
When a tumor begins to develop, macrophages attempt to block its growth. But often tumors hijack them and convert them into what are known as "tumor-associated macrophages", or TAMs for short.
Now corrupted, TAMs use their microRNAs to shield the tumor from the patient's immune system, helping it grow and metastasize. This phenomenon is common across many tumor types. It is one of the major obstacles in treating cancer, and often leads to a poor prognosis for the patient.
Reprogramming macrophages
Michele De Palma's team at EPFL found how to reclaim TAMs. The researchers genetically modified TAMs to remove their ability to produce microRNAs. As a result, the TAMs were reprogrammed dramatically. Instead of protecting the tumor, the TAMs now signaled the presence of the tumor to the immune system, triggering attacks against it - and did so very efficiently.
Using a bioinformatics approach, the researchers found that the most likely culprit was a small family of microRNAs, called Let-7. This offers a more specific target: blocking Let-7 microRNAs may help instruct the TAMs to stimulate anti-tumor immunity.
Interestingly, the researchers observed that reprogramming TAMs also stops cancer cells from leaving the primary tumor. This could mean that the approach can also prevent tumor metastasis, the most threatening aspect of cancer. Moreover, the researchers found that the re-educated TAMs could enhance the anti-tumoral efficacy of certain cancer immunotherapies, some of which are already approved for patients.
However, more work is needed to translate all these findings to actual therapies, especially since there is currently no way to block the Let-7 microRNAs selectively in TAMs. But De Palma's lab is now working with bioengineers at EPFL to design drugs that can target the Let-7 microRNAs specifically in the TAMs.
Therapeutic opportunities
Some of the most promising cancer treatments are immunotherapies, which are based on provoking or enhancing the patient's immune response against their tumor. "The most exciting finding was that TAM reprogramming greatly improved the efficacy of immunotherapy," says Michele De Palma. "Our results in experimental models of cancer suggest a new therapeutic strategy based on inhibiting the microRNA machinery - or the Let-7 microRNAs - specifically in the TAMs, which may unleash the power of mainstream immunotherapies, such as immune checkpoint inhibitors".
Original publication
Caroline Baer, Mario Leonardo Squadrito, Damya Laoui, Danielle Thompson, Sarah K. Hansen, Anna Kiialainen, Sabine Hoves, Carola H. Ries, Chia-Huey Ooi & Michele De Palma; "Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity"; Nature Cell Biology; 2016
Original publication
Caroline Baer, Mario Leonardo Squadrito, Damya Laoui, Danielle Thompson, Sarah K. Hansen, Anna Kiialainen, Sabine Hoves, Carola H. Ries, Chia-Huey Ooi & Michele De Palma; "Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity"; Nature Cell Biology; 2016
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Biotage AB and McMaster University sign joint agreement to develop new chemistry platform

Captain T Cell secures seed financing round - Start-up develops first-in-class efficacy-enhanced TCR-T cells for solid tumors that are not addressed by existing therapies

Gut bacteria affect ageing

Obulytix is developing a revolutionary solution for antibiotic resistance - Spin-off has built a platform that creates new ways to tackle bacterial infections
XOMA Licenses BCE Technology for Recombinant Protein Production to Wyeth
Light activated 'warhead' turns modest molecules into super protein killers - Novel research tool from Scripps Florida could significantly expand search for new therapies

Merck Invests More Than €440 Million and Expands its Membrane and Filtration Manufacturing in Ireland - “The investment in Cork is the biggest site investment in the history of our Life Science business”
Rondaxe and TD2 form strategic drug development alliance

Soft millirobots for minimally invasive surgery and drug delivery?

Nanoscale Velcro used for Molecule Transport
Johns Hopkins epilepsy study is first ResearchKit App to use Apple Watch
